Key Points
- Director Paul Schimmel bought 100,000 shares of aTyr Pharma at $0.50 each, spending $50,000 and increasing his stake by 14.72% to 779,143 shares.
- aTyr Pharma stock was trading around $0.49, near its 12-month low of $0.40, with a market cap of about $47.79 million.
- The company recently reported a quarterly loss of $(0.11) per share, which beat analyst expectations, while Wall Street currently has a Hold consensus rating on the stock.
aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction on Wednesday, May 27th. The shares were acquired at an average cost of $0.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director owned 779,143 shares of the company's stock, valued at $389,571.50. The trade was a 14.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
aTyr Pharma Trading Up 1.9%
Shares of ATYR stock opened at $0.49 on Friday. aTyr Pharma, Inc. has a 12 month low of $0.40 and a 12 month high of $7.29. The stock has a market cap of $47.79 million, a P/E ratio of -0.67 and a beta of 0.66. The company has a 50 day simple moving average of $0.74 and a two-hundred day simple moving average of $0.78.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. As a group, equities analysts forecast that aTyr Pharma, Inc. will post -0.66 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have commented on ATYR. Jefferies Financial Group reaffirmed a "buy" rating on shares of aTyr Pharma in a report on Friday, March 6th. Wall Street Zen raised shares of aTyr Pharma from a "sell" rating to a "hold" rating in a research note on Sunday, May 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of aTyr Pharma in a research note on Friday, May 22nd. Finally, Freedom Capital raised shares of aTyr Pharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $25.67.
Read Our Latest Research Report on ATYR
Institutional Trading of aTyr Pharma
A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. Profund Advisors LLC purchased a new stake in shares of aTyr Pharma in the third quarter worth $27,000. California State Teachers Retirement System purchased a new position in aTyr Pharma during the second quarter valued at $28,000. Renaissance Technologies LLC purchased a new position in aTyr Pharma during the first quarter valued at $32,000. ADAR1 Capital Management LLC grew its stake in aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company's stock valued at $40,000 after acquiring an additional 13,385 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC purchased a new position in aTyr Pharma during the fourth quarter valued at $41,000. 61.72% of the stock is owned by hedge funds and other institutional investors.
About aTyr Pharma
(
Get Free Report)
aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.
The company's research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
